

# Nathalie Percie du Sert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6930559/publications.pdf>

Version: 2024-02-01

32  
papers

8,577  
citations

331670

21  
h-index

434195

31  
g-index

35  
all docs

35  
docs citations

35  
times ranked

11903  
citing authors

#	ARTICLE	IF	CITATIONS
1	Building a Systematic Online Living Evidence Summary of COVID-19 Research. Journal of the European Association for Health Information and Libraries, 2021, 17, 21-26.	0.2	1
2	The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. BMC Veterinary Research, 2020, 16, 242.	1.9	136
3	The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 2020, 18, e3000410.	5.6	2,209
4	Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biology, 2020, 18, e3000411.	5.6	1,069
5	The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Journal of Physiology, 2020, 598, 3793-3801.	2.9	177
6	The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Experimental Physiology, 2020, 105, 1459-1466.	2.0	1,300
7	The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research*. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 1769-1777.	4.3	546
8	The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. British Journal of Pharmacology, 2020, 177, 3617-3624.	5.4	326
9	The ARRIVE guidelines 2.0: updated guidelines for reporting animal researchThe ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMJ Open Science, 2020, 44, e100115.	1.7	114
10	Framework for advancing rigorous research. ELife, 2020, 9, .	6.0	17
11	General Principles of Preclinical Study Design. Handbook of Experimental Pharmacology, 2019, 257, 55-69.	1.8	27
12	Revision of the ARRIVE guidelines: rationale and scope. BMJ Open Science, 2018, 2, e000002.	1.7	36
13	The NC3Rs gateway: Accelerating scientific discoveries with new 3Rs models and technologies. F1000Research, 2018, 7, 591.	1.6	3
14	A manifesto for reproducible science. Nature Human Behaviour, 2017, 1, 0021.	12.0	1,870
15	The Experimental Design Assistant. Nature Methods, 2017, 14, 1024-1025.	19.0	32
16	The IMPROVE Guidelines (Ischaemia Models: Procedural Refinements Of in Vivo Experiments). Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3488-3517.	4.3	128
17	The Experimental Design Assistant. PLoS Biology, 2017, 15, e2003779.	5.6	69
18	Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret. Journal of Translational Medicine, 2014, 12, 327.	4.4	12

#	ARTICLE	IF	CITATIONS
19	Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain. <i>British Journal of Pharmacology</i> , 2014, 171, 2951-2963.	5.4	163
20	Predicting the emetic liability of novel chemical entities: a comparative study. <i>British Journal of Pharmacology</i> , 2012, 165, 1848-1867.	5.4	45
21	Maximising the output of osteoarthritis research: the ARRIVE guidelines. <i>Osteoarthritis and Cartilage</i> , 2012, 20, 253-255.	1.3	9
22	Investigating the Effect of Emetic Compounds on Chemotaxis in Dictyostelium Identifies a Non-Sentient Model for Bitter and Hot Tastant Research. <i>PLoS ONE</i> , 2011, 6, e24439.	2.5	11
23	CardioPulse Articles. <i>European Heart Journal</i> , 2011, 32, 2333-2340.	2.2	0
24	Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT3 receptor antagonists. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 667-686.	2.3	71
25	Improving the reporting of animal research: when will we ARRIVE?. <i>DMM Disease Models and Mechanisms</i> , 2011, 4, 281-282.	2.4	5
26	Systematic review and meta-analysis of pre-clinical research: the need for reporting guidelines. <i>European Heart Journal</i> , 2011, 32, 2340.	2.2	2
27	Cannabinoid-induced reduction in antral pacemaker frequency: a telemetric study in the ferret. <i>Neurogastroenterology and Motility</i> , 2010, 22, 1257-e324.	3.0	10
28	Telemetry in a motion-induced sickness model implicates the abdominal vagus in motion-induced gastric dysrhythmia. <i>Experimental Physiology</i> , 2010, 95, 768-773.	2.0	33
29	Olvamil, a non-pungent vanilloid enhances the gastrointestinal toxicity of cisplatin in the ferret. <i>Toxicology Letters</i> , 2010, 192, 402-407.	0.8	10
30	Olvamil: A non-pungent TRPV1 activator has anti-emetic properties in the ferret. <i>Neuropharmacology</i> , 2010, 58, 383-391.	4.1	22
31	The delayed phase of cisplatin-induced emesis is mediated by the area postrema and not the abdominal visceral innervation in the ferret. <i>Neuroscience Letters</i> , 2009, 465, 16-20.	2.1	28
32	Reduced normogastric electrical activity associated with emesis: A telemetric study in ferrets. <i>World Journal of Gastroenterology</i> , 2009, 15, 6034.	3.3	31